Fondaparinux

BreastfeedingGeriatricPediatric
  • TRADE NAME: Arixtra (Mylan)
  • INDICATIONS: Prophylaxis of deep vein thrombosis
  • CLASS: Anticoagulant, Heparinoid
  • HALF-LIFE: 17–21 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Abciximab, Anagrelide, Anticoagulants, Cilostazol, Clopidogrel, Dabigatran, Dipyridamole, Eptifibatide, Nandrolone, Salicylates, Ticlopidine, Tirofiban

PREGNANCY CATEGORY: B

SPINAL/EPIDURAL HEMATOMAS

See full prescribing information for complete boxed warning.

Our database has 14 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of fondaparinux in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 09/19/2018

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top